Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination), and Segment Forecasts, 2016 - 2022
This report can be delivered to the clients within 120 Business Hours
The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the forecast period. Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.
Hyperlipidemia is the most common type of dyslipidemia and is generally caused by abnormally high lipid levels in the blood. This condition can occur due to genetic factors (primary hyperlipidemia) as well as other factors such as poor diet and unhealthy lifestyle (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia.
Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.
Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs. However, new product launches are anticipated to continue to drive the market. Several novel mechanisms of action such as ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3 are being investigated for their potential for treatment of hyperlipidemia as well as for reducing the risk of CVD.
Further key findings from the report suggest:
The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the forecast period. Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.
Hyperlipidemia is the most common type of dyslipidemia and is generally caused by abnormally high lipid levels in the blood. This condition can occur due to genetic factors (primary hyperlipidemia) as well as other factors such as poor diet and unhealthy lifestyle (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia.
Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.
Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs. However, new product launches are anticipated to continue to drive the market. Several novel mechanisms of action such as ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3 are being investigated for their potential for treatment of hyperlipidemia as well as for reducing the risk of CVD.
Further key findings from the report suggest:
- Statins dominated the drug classes in 2016 owing to their high usage as the first line of therapy
- Recent launch of PCSK9 inhibitors, such as Repatha and Praluent, is likely to change the current therapeutic scenario due to their improved efficacy and safety profile
- PCSK9 inhibitors are expected to displace existing expensive therapies, lomitapide, and mipomersen for the treatment of homozygous FH patients
- Europe was the leading regional market in 2016. It is estimated to maintain its dominance till 2022 owing to high prevalence of hypercholesterolemia
- There are fewer growth opportunities in Japan due to unavailability of key pipeline drugs such as bempedoic acid
- AstraZeneca; Merck & Co., Inc.; Pfizer, Inc.; DAIICHI SANKYO COMPANY, LIMITED; Amgen, Inc.; and Sanofi are some of the key players operating in this market
- Amgen, Inc.; Sanofi; and Esperion are expected to have the highest shares in this market by 2022
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Types:
3.1.1.1 Type I
3.1.1.2 Type II
3.1.1.3 Type III
3.1.1.4 Type IV
3.1.1.5 Type V
3.1.2 Complications
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, & EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, & EU5)
3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, & EU5)
CHAPTER 4 GLOBAL HYPERLIPIDEMIA DRUGS MARKET OVERVIEW
4.1 Introduction and Market Overview
4.1.1 Segmentation by region
4.1.1.1 U.S.
4.1.1.2 U.K.
4.1.1.3 Germany
4.1.1.4 Spain
4.1.1.5 France
4.1.1.6 Italy
4.1.1.7 Japan
4.1.2 Segmentation by drug class
4.1.2.1 Statins
4.1.2.2 Bile acid sequestrants
4.1.2.3 Cholesterol absorption inhibitors
4.1.2.4 Fibric acid derivatives
4.1.2.5 PCSK9 inhibitors
4.1.2.6 Combination
4.1.2.7 Miscellaneous antihyperlipidemic agents
4.1.3 Market size & forecast
4.1.4 Sales performance
4.1.5 Market share distribution
4.1.6 Market dynamics among leading brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (2013 - 2017 YTD)
4.5 Pricing and Reimbursement
4.6 SWOT analysis
CHAPTER 5 HYPERLIPIDEMIA DRUGS MARKET: PIPELINE INTELLIGENCE
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.2 Key R&D trends
5.1.2.1 PCSK9 inhibition
5.1.2.2 Antisense therapy
5.1.2.3 Gene silencing
5.1.2.4 Omega - 3 fatty acid
5.1.2.5 ATP - citrate lyase
5.1.2.6 DGAT2 inhibitor
5.1.2.7 ANGPTL - 3 antibody
5.2 Promising Drugs in Pipeline
5.2.1 Late stage pipeline and sales forecast
5.2.2 Profile of disruptive drugs
5.2.2.1 Repatha
5.2.2.2 Praluent
5.2.2.3 Bempedoic acid
5.2.2.4 K - 877/Pemafibrate
CHAPTER 6 COMPANY PROFILES
6.1 AstraZeneca
6.1.1 Company overview
6.1.2 Current product portfolio
6.1.3 Product sales forecast through 2022
6.1.4 Key facts
6.1.4.1 Crestor
6.1.4.2 Epanova
6.1.5 Company - Key news flow
6.1.6 Pipeline view
6.1.7 Pipeline forecast
6.1.8 Catalysts and event calendar
6.1.9 SWOT analysis
6.2 Merck
6.2.1 Company overview
6.2.2 Current product portfolio
6.2.3 Product sales forecast through 2022
6.2.4 Key facts
6.2.4.1 Zetia
6.2.4.2 Zocor
6.2.4.3 Vytorin
6.2.5 Company - Key news flow
6.2.6 Catalysts and event calendar
6.2.7 SWOT analysis
6.3 Pfizer
6.3.1 Company overview
6.3.2 Current product portfolio
6.3.3 Product sales forecast through 2022
6.3.4 Key facts
6.3.4.1 Lipitor
6.3.4.2 Caduet
6.3.5 Company - Key news flow
6.3.6 Pipeline view
6.3.7 Pipeline forecast
6.3.8 Catalysts and event calendar
6.3.9 SWOT analysis
6.4 Daiichi Sankyo
6.4.1 Company overview
6.4.2 Current product portfolio
6.4.3 Product sales forecast through 2022
6.4.4 Key facts
6.4.4.1 Welchol
6.4.4.2 Mevalotin
6.4.5 SWOT analysis
6.5 Amgen
6.5.1 Company overview
6.5.2 Current product portfolio
6.5.3 Product sales forecast through 2022
6.5.4 Key facts
6.5.4.1 Repatha
6.5.5 Company - Key news flow
6.5.6 Pipeline view
6.5.7 Pipeline forecast
6.5.8 SWOT analysis
6.6 Sanofi
6.6.1 Company overview
6.6.2 Current product portfolio
6.6.3 Product sales forecast through 2022
6.6.4 Key facts
6.6.4.1 Praluent
6.6.5 Company - Key news flow
6.6.6 Pipeline view
6.6.7 Pipeline forecast
6.6.8 Catalysts and event calendar
6.6.9 SWOT analysis
CHAPTER 7 MARKET OUTLOOK
7.1 What the future holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The Road Ahead
1.1 Information procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Types:
3.1.1.1 Type I
3.1.1.2 Type II
3.1.1.3 Type III
3.1.1.4 Type IV
3.1.1.5 Type V
3.1.2 Complications
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, & EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, & EU5)
3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, & EU5)
CHAPTER 4 GLOBAL HYPERLIPIDEMIA DRUGS MARKET OVERVIEW
4.1 Introduction and Market Overview
4.1.1 Segmentation by region
4.1.1.1 U.S.
4.1.1.2 U.K.
4.1.1.3 Germany
4.1.1.4 Spain
4.1.1.5 France
4.1.1.6 Italy
4.1.1.7 Japan
4.1.2 Segmentation by drug class
4.1.2.1 Statins
4.1.2.2 Bile acid sequestrants
4.1.2.3 Cholesterol absorption inhibitors
4.1.2.4 Fibric acid derivatives
4.1.2.5 PCSK9 inhibitors
4.1.2.6 Combination
4.1.2.7 Miscellaneous antihyperlipidemic agents
4.1.3 Market size & forecast
4.1.4 Sales performance
4.1.5 Market share distribution
4.1.6 Market dynamics among leading brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (2013 - 2017 YTD)
4.5 Pricing and Reimbursement
4.6 SWOT analysis
CHAPTER 5 HYPERLIPIDEMIA DRUGS MARKET: PIPELINE INTELLIGENCE
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.2 Key R&D trends
5.1.2.1 PCSK9 inhibition
5.1.2.2 Antisense therapy
5.1.2.3 Gene silencing
5.1.2.4 Omega - 3 fatty acid
5.1.2.5 ATP - citrate lyase
5.1.2.6 DGAT2 inhibitor
5.1.2.7 ANGPTL - 3 antibody
5.2 Promising Drugs in Pipeline
5.2.1 Late stage pipeline and sales forecast
5.2.2 Profile of disruptive drugs
5.2.2.1 Repatha
5.2.2.2 Praluent
5.2.2.3 Bempedoic acid
5.2.2.4 K - 877/Pemafibrate
CHAPTER 6 COMPANY PROFILES
6.1 AstraZeneca
6.1.1 Company overview
6.1.2 Current product portfolio
6.1.3 Product sales forecast through 2022
6.1.4 Key facts
6.1.4.1 Crestor
6.1.4.2 Epanova
6.1.5 Company - Key news flow
6.1.6 Pipeline view
6.1.7 Pipeline forecast
6.1.8 Catalysts and event calendar
6.1.9 SWOT analysis
6.2 Merck
6.2.1 Company overview
6.2.2 Current product portfolio
6.2.3 Product sales forecast through 2022
6.2.4 Key facts
6.2.4.1 Zetia
6.2.4.2 Zocor
6.2.4.3 Vytorin
6.2.5 Company - Key news flow
6.2.6 Catalysts and event calendar
6.2.7 SWOT analysis
6.3 Pfizer
6.3.1 Company overview
6.3.2 Current product portfolio
6.3.3 Product sales forecast through 2022
6.3.4 Key facts
6.3.4.1 Lipitor
6.3.4.2 Caduet
6.3.5 Company - Key news flow
6.3.6 Pipeline view
6.3.7 Pipeline forecast
6.3.8 Catalysts and event calendar
6.3.9 SWOT analysis
6.4 Daiichi Sankyo
6.4.1 Company overview
6.4.2 Current product portfolio
6.4.3 Product sales forecast through 2022
6.4.4 Key facts
6.4.4.1 Welchol
6.4.4.2 Mevalotin
6.4.5 SWOT analysis
6.5 Amgen
6.5.1 Company overview
6.5.2 Current product portfolio
6.5.3 Product sales forecast through 2022
6.5.4 Key facts
6.5.4.1 Repatha
6.5.5 Company - Key news flow
6.5.6 Pipeline view
6.5.7 Pipeline forecast
6.5.8 SWOT analysis
6.6 Sanofi
6.6.1 Company overview
6.6.2 Current product portfolio
6.6.3 Product sales forecast through 2022
6.6.4 Key facts
6.6.4.1 Praluent
6.6.5 Company - Key news flow
6.6.6 Pipeline view
6.6.7 Pipeline forecast
6.6.8 Catalysts and event calendar
6.6.9 SWOT analysis
CHAPTER 7 MARKET OUTLOOK
7.1 What the future holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The Road Ahead
LIST OF TABLES
TABLE 1 Current hyperlipidemia prevalence for seven major markets - 2016
TABLE 2 Current hyperlipidemia incidence for seven major markets - 2016
TABLE 3 Forecast hyperlipidemia prevalence for seven major markets 2016 - 2022
TABLE 4 Forecast hyperlipidemia incidence for seven major markets 2016 - 2022
TABLE 5 Statin classification by intensity
TABLE 6 Hyperlipidemia drugs market size and forecast (in US million)
TABLE 7 Geographic sales performance by seven major markets (in US million)
TABLE 8 Hyperlipidemia drugs market by drug class (in US million)
TABLE 9 Forecast sales of leading brands (in US million)
TABLE 10 Global hyperlipidemia pipeline forecast
TABLE 11 Global hyperlipidemia pipeline sales forecast (in US million)
TABLE 12 Hyperlipidemia sales forecast by company (in US million)
TABLE 13 Hyperlipidemia drugs market share by company (in US million)
TABLE 14 Hyperlipidemia patent expiry schedule
TABLE 15 M&A, deal landscape
TABLE 16 Leading antihyperlipidemic drugs in pipeline
TABLE 17 Late-stage pipeline and sales forecast
TABLE 18 Profile of disruptive drug: Repatha
TABLE 19 Profile of disruptive drug: Praluent
TABLE 20 Profile of disruptive drug: Bempedoic Acid
TABLE 21 Profile of disruptive drug: Pemafibrate
TABLE 22 Product portfolio: Crestor
TABLE 23 Product portfolio: Epanova
TABLE 24 Crestor sales forecast through 2022
TABLE 25 AstraZeneca pipeline view
TABLE 26 AstraZeneca catalysts and event calendar
TABLE 27 Product portfolio: Zetia
TABLE 28 Product portfolio: Zocor
TABLE 29 Product portfolio: Vytorin
TABLE 30 Zetia sales forecast through 2022
TABLE 31 Zocor sales forecast through 2022
TABLE 32 Vytorin sales forecast through 2022
TABLE 33 Merck catalysts and event calendar
TABLE 34 Product portfolio: Lipitor
TABLE 35 Product portfolio: Caduet
TABLE 36 Lipitor sales forecast through 2022
TABLE 37 Caduet sales forecast through 2022
TABLE 38 Pfizer pipeline view
TABLE 39 Pfizer catalysts and event calendar
TABLE 40 Product portfolio: Welchol
TABLE 41 Product portfolio: Mevalotin
TABLE 42 Welchol sales forecast through 2022
TABLE 43 Product portfolio: Repatha
TABLE 44 Repatha sales forecast through 2022
TABLE 45 Amgen pipeline view
TABLE 46 Product portfolio: Praluent
TABLE 47 Praluent sales forecast through 2022
TABLE 48 Sanofi pipeline view
TABLE 49 Sanofi catalysts and event calendar
TABLE 1 Current hyperlipidemia prevalence for seven major markets - 2016
TABLE 2 Current hyperlipidemia incidence for seven major markets - 2016
TABLE 3 Forecast hyperlipidemia prevalence for seven major markets 2016 - 2022
TABLE 4 Forecast hyperlipidemia incidence for seven major markets 2016 - 2022
TABLE 5 Statin classification by intensity
TABLE 6 Hyperlipidemia drugs market size and forecast (in US million)
TABLE 7 Geographic sales performance by seven major markets (in US million)
TABLE 8 Hyperlipidemia drugs market by drug class (in US million)
TABLE 9 Forecast sales of leading brands (in US million)
TABLE 10 Global hyperlipidemia pipeline forecast
TABLE 11 Global hyperlipidemia pipeline sales forecast (in US million)
TABLE 12 Hyperlipidemia sales forecast by company (in US million)
TABLE 13 Hyperlipidemia drugs market share by company (in US million)
TABLE 14 Hyperlipidemia patent expiry schedule
TABLE 15 M&A, deal landscape
TABLE 16 Leading antihyperlipidemic drugs in pipeline
TABLE 17 Late-stage pipeline and sales forecast
TABLE 18 Profile of disruptive drug: Repatha
TABLE 19 Profile of disruptive drug: Praluent
TABLE 20 Profile of disruptive drug: Bempedoic Acid
TABLE 21 Profile of disruptive drug: Pemafibrate
TABLE 22 Product portfolio: Crestor
TABLE 23 Product portfolio: Epanova
TABLE 24 Crestor sales forecast through 2022
TABLE 25 AstraZeneca pipeline view
TABLE 26 AstraZeneca catalysts and event calendar
TABLE 27 Product portfolio: Zetia
TABLE 28 Product portfolio: Zocor
TABLE 29 Product portfolio: Vytorin
TABLE 30 Zetia sales forecast through 2022
TABLE 31 Zocor sales forecast through 2022
TABLE 32 Vytorin sales forecast through 2022
TABLE 33 Merck catalysts and event calendar
TABLE 34 Product portfolio: Lipitor
TABLE 35 Product portfolio: Caduet
TABLE 36 Lipitor sales forecast through 2022
TABLE 37 Caduet sales forecast through 2022
TABLE 38 Pfizer pipeline view
TABLE 39 Pfizer catalysts and event calendar
TABLE 40 Product portfolio: Welchol
TABLE 41 Product portfolio: Mevalotin
TABLE 42 Welchol sales forecast through 2022
TABLE 43 Product portfolio: Repatha
TABLE 44 Repatha sales forecast through 2022
TABLE 45 Amgen pipeline view
TABLE 46 Product portfolio: Praluent
TABLE 47 Praluent sales forecast through 2022
TABLE 48 Sanofi pipeline view
TABLE 49 Sanofi catalysts and event calendar
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary, 2016
FIG. 8 Current prevalence for seven major markets - 2016
FIG. 9 Current incidence for seven major markets - 2016
FIG. 10 Market segmentation & scope
FIG. 11 Geographic sales performance by seven major markets 2016
FIG. 12 Hyperlipidemia drugs market by drug class
FIG. 13 Hyperlipidemia market share by company 2016 - 2022
FIG. 14 Market trends & outlook
FIG. 15 Market driver relevance analysis (Current & future impact)
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 SWOT analysis (Hyperlipidemia drugs market)
FIG. 18 SWOT analysis (AstraZeneca)
FIG. 19 SWOT analysis (Merck)
FIG. 20 SWOT analysis (Pfizer)
FIG. 21 SWOT analysis (Daiichi Sankyo)
FIG. 22 SWOT analysis (Amgen)
FIG. 23 SWOT analysis (Sanofi)
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary, 2016
FIG. 8 Current prevalence for seven major markets - 2016
FIG. 9 Current incidence for seven major markets - 2016
FIG. 10 Market segmentation & scope
FIG. 11 Geographic sales performance by seven major markets 2016
FIG. 12 Hyperlipidemia drugs market by drug class
FIG. 13 Hyperlipidemia market share by company 2016 - 2022
FIG. 14 Market trends & outlook
FIG. 15 Market driver relevance analysis (Current & future impact)
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 SWOT analysis (Hyperlipidemia drugs market)
FIG. 18 SWOT analysis (AstraZeneca)
FIG. 19 SWOT analysis (Merck)
FIG. 20 SWOT analysis (Pfizer)
FIG. 21 SWOT analysis (Daiichi Sankyo)
FIG. 22 SWOT analysis (Amgen)
FIG. 23 SWOT analysis (Sanofi)
